Is DaVita (DVA) Still Reasonable After Its 139% Three Year Run?

DaVita has delivered a strong multi year share price run, and with the stock recently closing at US$183.64 the live question is whether that climb is still supported by its earnings power. Over the past 3 years the stock has gained 139.2%, which puts real pressure on the current earnings base to justify where the valuation now sits. DaVita's recent backing of the HHS Kidney Care National Plan and its push into clinical research and value based kidney care can influence how investors view the...